Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Hookipa Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
HOOK
Nasdaq
2834
https://www.hookipapharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Hookipa Pharma Inc
Time To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Outlook
- Mar 24th, 2024 12:50 pm
HOOKIPA Pharma Inc. (HOOK) Reports Q4 Loss, Tops Revenue Estimates
- Mar 22nd, 2024 12:15 pm
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Mar 22nd, 2024 11:01 am
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
- Mar 6th, 2024 12:01 pm
Absci Corporation (ABSI) Surges 10.0%: Is This an Indication of Further Gains?
- Mar 1st, 2024 11:49 am
All You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong Buy
- Feb 2nd, 2024 5:00 pm
Best Momentum Stocks to Buy for February 2nd
- Feb 2nd, 2024 3:00 pm
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
- Jan 29th, 2024 1:54 pm
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
- Jan 29th, 2024 1:01 pm
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
- Jan 16th, 2024 12:01 pm
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
- Dec 21st, 2023 12:01 pm
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
- Nov 20th, 2023 12:01 pm
HOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023
- Nov 9th, 2023 1:39 pm
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- Nov 9th, 2023 12:01 pm
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
- Nov 3rd, 2023 4:01 pm
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
- Nov 2nd, 2023 8:01 pm
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
- Oct 22nd, 2023 10:01 am
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
- Oct 18th, 2023 11:01 am
HOOKIPA Announces Executive Leadership Change
- Sep 13th, 2023 12:45 pm
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Sep 12th, 2023 11:01 am
Scroll